Fox Chase Cancer Center News

Fox Chase Cancer Center, part of the Temple Health, has received a five-year renewal of its prestigious Cancer Center Support Grant (CCSG) from the National Cancer Institute (NCI), reaffirming its designation as an NCI-designated Comprehensive Cancer Center—an elite status held by only 57 centers nationwide.

In a study recently published by researchers at Fox Chase Cancer Center, patients being treated for retroperitoneal sarcoma at multiple facilities experienced longer delays between diagnosis and treatment and traveled farther to receive treatment, but their overall survival rates were equivalent to patients receiving nonfragmented care.

Pooja Ghatalia, MD, an Associate Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has been granted funding from the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP) to study a new approach to treatment for patients with metastatic urothelial carcinoma.

A study presented by researchers at Fox Chase Cancer Center finds that the type of therapy a patient receives before surgery for pancreatic ductal adenocarcinoma has more of an impact on postoperative outcomes and survival than the duration of treatment.

Jaylin Staunton, MS, RD, LDN, CNSC, Lead Clinical Dietitian Specialist at Fox Chase Cancer Center, was awarded the Recognized Young Dietitian of the Year Award by the Pennsylvania Academy of Nutrition and Dietetics.

Alexander Kutikov, MD, FACS, Chair of the Department of Urology at Fox Chase Cancer Center, recently co-edited and contributed to a new edition of Urologic Clinics of North America Focused on Adrenal Tumor Diagnosis and Treatment.

Adria Hasan, PhD, a postdoctoral associate at Fox Chase Cancer Center, was recently honored with the American Association for Cancer Research’s (AACR) John Kincade Scholarship Fund Scholar-in-Training Award.

Parastomal hernia is a common complication among patients who undergo bladder removal and ileal conduit urinary diversion. Now, a new study presented by Fox Chase Cancer Center clinicians at the American Urological Association’s (AUA) Annual Meeting supports the use of partially absorbable synthetic, non-biologic parastomal mesh to significantly reduce this risk in real-world practice.